Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

医学 帕金森病 安慰剂 双盲 临床试验 物理疗法 内科学 疾病 替代医学 病理
作者
Michael J. Soileau,Jason L. Aldred,Kumar Budur,Nahome Fisseha,Victor S.C. Fung,Anna Jeong,Thomas Edmund Kimber,Kevin J. Klos,Irene Litvan,Daniel O'Neill,Weining Robieson,Meredith Spindler,David G. Standaert,Saritha Talapala,Okeanis Vaou,Hui Zheng,Maurizio Facheris,Robert A. Hauser
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:21 (12): 1099-1109 被引量:286
标识
DOI:10.1016/s1474-4422(22)00400-8
摘要

Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation of levodopa and carbidopa prodrugs that is delivered as a 24-h/day continuous subcutaneous infusion, and we aimed to assess the safety and efficacy of this formulation in patients with advanced Parkinson's disease.A 12-week randomised, double-blind, double-dummy, active-controlled study was done at 65 academic and community study centres in the USA and Australia. Patients with levodopa-responsive advanced Parkinson's disease inadequately controlled on current therapy, including at least 2·5 h of average daily off time, were randomly assigned (1:1) to continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo or to oral immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution. Randomisation was stratified by site by means of a permutated-block schedule with a block size of two. The participants, treating investigators, study site personnel, and sponsor were masked to treatment group allocation. The primary and first key secondary endpoint in the hierarchical testing strategy were change from baseline to week 12 in on time without troublesome dyskinesia and off time, respectively; both endpoints were evaluated by an intention-to-treat analysis applying a mixed model for repeated measures analysis. Safety and tolerability were assessed throughout the study. The study is completed and is listed on ClinicalTrials.gov, NCT04380142.Between Oct 19, 2020, and Sept 29, 2021, of 270 participants screened and 174 enrolled, 141 were randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n=74) or oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67). Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (-2·75 [0·50] vs -0·96 [0·49] h; difference -1·79 h, -3·03 to -0·54; p=0·0054). Hierarchical testing ended after the first secondary endpoint. Adverse events were reported in 63 (85%) of 74 patients in the foslevodopa-foscarbidopa group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse events were similar between the groups (six [8%] of 74 vs four [6%] of 67, respectively). The most frequent adverse events in the foslevodopa-foscarbidopa group were infusion site adverse events (erythema 20 [27%]), pain 19 [26%]), cellulitis (14 [19%]), and oedema (nine [12%]), most of which were non-serious and mild-moderate in severity. The only system organ class that had more than one serious adverse event in the foslevodopa-foscarbidopa group was infections and infestations (catheter site cellulitis [one [1%]] and infusion site cellulitis [one [1%]). Adverse events led to premature discontinuation of study drug in 16 (22%) of 74 participants in the foslevodopa-foscarbidopa group versus one (1%) of 67 participants in the oral levodopa-carbidopa group.Foslevodopa-foscarbidopa improved motor fluctuations, with benefits in both on time without troublesome dyskinesia and off time. Foslevodopa-foscarbidopa has a favourable benefit-risk profile and represents a potential non-surgical alternative for patients with advanced Parkinson's disease.AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虚幻的方盒完成签到,获得积分10
刚刚
Ava的应助被欣灵采纳,获得15
刚刚
科研通AI6.3的应助被LIUDAN采纳,获得10
刚刚
搞怪灯泡发布了新的文献求助30
1秒前
Twinkle发布了新的文献求助10
2秒前
linr_terran发布了新的文献求助10
2秒前
斯文败类的应助被超级无敌采纳,获得30
2秒前
Y元郁Y完成签到,获得积分20
2秒前
leoan完成签到,获得积分0
3秒前
3秒前
3秒前
4秒前
4秒前
wufel2完成签到,获得积分0
4秒前
王不留行完成签到 ,获得积分10
5秒前
学霸业的应助被YYYY采纳,获得10
7秒前
大方酶完成签到,获得积分10
7秒前
木子完成签到,获得积分20
7秒前
万能图书馆的应助被科研小白采纳,获得10
8秒前
科研通AI6.3的应助被向分公司采纳,获得10
8秒前
JJ完成签到,获得积分10
8秒前
8秒前
woli发布了新的文献求助10
8秒前
Jun的应助被Xk采纳,获得10
9秒前
9秒前
9秒前
阔达晓蓝发布了新的文献求助10
10秒前
10秒前
12秒前
丘比特的应助被kalani采纳,获得10
12秒前
EK发布了新的文献求助10
12秒前
上官若男的应助被开心德地采纳,获得10
13秒前
yskm完成签到,获得积分20
13秒前
kkkk完成签到,获得积分10
13秒前
失眠善若完成签到,获得积分10
13秒前
务实的问丝完成签到,获得积分10
13秒前
CipherSage的应助被Aiserlyn采纳,获得30
14秒前
15秒前
6哈发布了新的文献求助10
16秒前
我是老大的应助被开心德地采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509